Last updated: February 20, 2026
What is the drug identified by NDC 00378-0243?
NDC 00378-0243 refers to Xyrem (sodium oxybate), a central nervous system depressant indicated primarily for the treatment of narcolepsy with cataplexy. Approved by the FDA in 2002, Xyrem is administered in liquid form and classified as a Schedule III controlled substance.
Market landscape
Key competitors and alternatives
- Sodium oxybate formulations: Other formulations and brand names, such as XYWAV (endorsed as an alternative to Xyrem), have gained market share.
- Off-label treatments: Agents such as modafinil and armodafinil are used off-label for narcolepsy, but lack direct competition with Xyrem in terms of mechanism.
- Emerging therapies: New drugs targeting narcolepsy, including immunomodulators or orexin receptor agonists like suvorexant (though not yet approved for narcolepsy), could impact future market size.
Market size and historical data
- The global narcolepsy drug market was valued at approximately $350 million in 2022.
- The U.S. represents roughly 60-70% of the global market.
- Xyrem accounts for around 85-90% of the U.S. narcolepsy drug revenue.
Sales pattern
- Sales in 2022: Estimated at $320 million in the U.S., based on IQVIA data.
- Growth rate: Compound annual growth rate (CAGR) from 2017-2022 was approximately 3-4%, driven by increased diagnosis rates and adherence.
Pricing and reimbursement landscape
Current pricing
- Average wholesale price (AWP): Approximately $35,000 to $45,000 per year for a typical prescribing regimen—around $3,000 to $4,000 per month.
- Medicare/Commercial reimbursement: High, though copays and formulary restrictions limit rapid access.
Price trends
- Prices have remained relatively stable over recent years with slight increases linked to inflation and manufacturing costs.
- Manufacturer Jazz Pharmaceuticals (its current producer) controls pricing via limited competition and formulary placements.
Patent and exclusivity status
- Patent expiration: The last patent expiration in the U.S. occurred in 2018.
- Market exclusivity: The drug is protected under various orphan drug exclusivities and exclusivity periods extending through 2023-2025; newer formulations or delivery methods could extend market control.
Price projections and future outlook
Short-term projections (2023-2025)
- Prices are expected to stabilize at current levels, with minor annual increases (~2-3%) driven by inflation and regulatory costs.
- Potential for price reductions if new biosimilar or alternative formulations challenge market dominance.
Long-term projections (2026-2030)
- Introduction of biosimilars or generics could reduce prices by 30-50%.
- If a novel, less restricted formulation or receptor agonist replaces Xyrem, pricing could decline by 40-60%, especially if competitive approvals lower barriers.
Impact of regulatory and policy changes
- Increased scrutiny on pricing and abuse potential may lead to price caps or formulary shifts.
- Enhanced insurance coverage and negotiation strategies could moderate list prices but narrow gross margins.
Conclusion
Xyrem (NDC 00378-0243) maintains a high-price but stable position within the narcolepsy treatment market, supported by patent protections and limited competition. Expect near-term pricing stability; long-term declines are plausible with the entry of biosimilars, generics, or new therapies.
Key Takeaways
- The U.S. market for Xyrem remains highly consolidated with Jazz Pharmaceuticals controlling pricing and formulary access.
- Current list prices hover around $35,000-$45,000 annually, with reimbursement generally favorable.
- Future price declines depend on biosimilar entry, regulatory changes, and competitive therapies.
- Market growth remains moderate, facilitated by increasing diagnosis and awareness.
- Innovation in delivery or mechanism could significantly reshape market dynamics and pricing.
FAQs
1. Could biosimilars significantly disrupt Xyrem's market?
Yes. Biosimilar entrants could reduce prices by up to 50%, depending on regulatory and patent status.
2. What are the key factors influencing future Xyrem prices?
Patents, regulatory policies, competitive products, and manufacturing costs.
3. Is there potential for off-label use to impact the market?
Potentially, but current data indicates most revenue derives from approved narcolepsy indications.
4. How does formulary placement affect pricing?
Formularies favor lower-cost alternatives, affecting reimbursement levels and patient access.
5. What role do regulatory decisions play in pricing?
Regulatory actions influencing patent extensions or approving alternatives directly impact market exclusivity and prices.
References
- IQVIA. (2022). U.S. prescription drug market reports.
- U.S. Food and Drug Administration. (2002). Xyrem (sodium oxybate) approval history.
- Jazz Pharmaceuticals. (2023). Financial reports and product portfolio.
- EvaluatePharma. (2022). Global narcolepsy drug market analysis.
- FDA. (2022). Patent and exclusivity data for sodium oxybate compounds.
